Drawing for TOCUDIN

USPTO serial 79007265

TOCUDIN

Reviewed by CopyMark Law Group

Reg. 3095820Status 404
Filing date
Status date
Registration date
May 23, 2006
Examiner
PINO, BRIAN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TOCUDIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joyce W. Jenzano

JOYCE W JENZANO MOORE & VAN ALLEN PLLC430 DAVIS DR STE 500MORRISVILLE, NC 27560UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Veterinary preparations and medicines for veterinary purposes, namely, anaesthetics and analgesics, for the treatment of pain, irritation from mechanical, chemical or ischemic stimulation and inflammation, and preparations for the treatment of withdrawal symptoms, and the treatment of drug dependency, and for abstaining from narcotics and other drugs; chemical preparations for veterinary purposes; chemical reagents for veterinary purposes; anaesthetics for surgical use, non surgical use, general, local and topical anaesthetics; syrups, namely, anaesthetic syrups, analgesic syrups, and syrups for the suppression of symptoms of drug withdrawal and for abstaining from narcotics and other drugs; chemico-pharmaceutical and pharmaceutical preparations, namely, anaesthetics and analgesics for the treatment of pain, or irritation from mechanical, chemical or ischemic stimulation, or inflammation, and for the treatment of withdrawal symptoms, the treatment of drug dependency, for abstaining from narcotics and other drugs, and for the treatment of pain or inflammation arising from cancer or cancer treatment; salts of biologically active organic compounds for medical purposes; gelatine based dosage forms containing pharmaceutical or chemico-pharmaceutical preparations or medicines for the treatment of pain and irritation and for the treatment of drug dependency and suppression of the symptoms of drug withdrawal; lozenges and pastilles for medical purposes, namely medicated lozenges, cough lozenges, throat lozenges, and lozenges and pastilles containing pharmaceutical or chemico-pharmaceutical preparations; medically prescribed or legally available synthetic narcotics; medically prescribed or legally available narcotics for the treatment of pain and irritation and for the treatment of drug dependency and suppression of the symptoms of drug withdrawal; ointments and lotions for pharmaceutical purposes, namely, anti-itch ointments, haemorrhoidal ointments, medicated rash ointments, ointments and lotions for the treatment of pain, irritation or discomfort; pectin containing preparations for pharmaceutical purposes, namely, anaesthetics and analgesics for the treatment of pain, irritation from mechanical, chemical or ischemic stimulation, or inflammation, and preparations for the treatment of withdrawal symptoms, the treatment of drug dependency, for abstaining from narcotics and other drugs, and for the treatment of pain or inflammation arising from cancer or cancer treatment; pills for pharmaceutical purposes, namely for the administration of pharmaceutical and chemico-pharmaceutical preparations in the nature of anaesthetics, analgesics and anti-irritant drugs, and preparations for the treatment of pain and drug dependency; poisons namely biological toxins or synthetic analogues or derivatives thereof for the treatment or amelioration of medical conditions, pain, irritation or discomfort, and for abstaining from drug dependency; sedatives; suppositories; medicines for human purposes, namely, anaesthetics and analgesics, for the treatment of pain, irritation from mechanical, chemical or ischemic stimulation and inflammation, and preparations for the treatment of withdrawal symptoms, the treatment of drug dependency, for abstaining from narcotics and other drugs, and for the treatment of pain or inflammation arising from cancer or cancer treatment; biological preparations for medical purposes; chemical preparations for pharmaceutical purposes; gases for medical purposes; chemical preparations for medical purposes; chemical reagents for medical purposesSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 1, 2015INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Apr 10, 2015DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Apr 9, 2015DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Apr 9, 2015DETHDEATH OF INTERNATIONAL REGISTRATION—
Aug 23, 2014XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Aug 23, 2014XXCRGENERIC MADRID TRANSACTION CREATED—
May 6, 2014INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 6, 2013C71TCANCELLED SECTION 71—
Dec 6, 2007FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 23, 2007FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 23, 2007FIMPFINAL DISPOSITION PROCESSED—
Dec 11, 2006FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 23, 2006R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 28, 2006PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 15, 2006DOCKASSIGNED TO EXAMINER—
Feb 8, 2006NPUBNOTICE OF PUBLICATION—
Dec 16, 2005PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Nov 21, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 18, 2005ALIEASSIGNED TO LIE—
Nov 14, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 14, 2005GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 14, 2005CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 25, 2005TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 13, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 13, 2005TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 13, 2005TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 13, 2005ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 13, 2005REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 2, 2005RFNTREFUSAL PROCESSED BY IB—
Apr 18, 2005CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 15, 2005CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 11, 2005DOCKASSIGNED TO EXAMINER—
Feb 16, 2005DOCKASSIGNED TO EXAMINER—
Jan 18, 2005NWAPNEW APPLICATION ENTERED—
Jan 13, 2005REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance